WO2008157664A1 - Procédé de traitement de micro-organismes et/ou d'agents infectieux - Google Patents

Procédé de traitement de micro-organismes et/ou d'agents infectieux Download PDF

Info

Publication number
WO2008157664A1
WO2008157664A1 PCT/US2008/067441 US2008067441W WO2008157664A1 WO 2008157664 A1 WO2008157664 A1 WO 2008157664A1 US 2008067441 W US2008067441 W US 2008067441W WO 2008157664 A1 WO2008157664 A1 WO 2008157664A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
polymer composition
film
microorganism
substrate
Prior art date
Application number
PCT/US2008/067441
Other languages
English (en)
Inventor
Garry Edgington
Snezna Rogelj
Hong Tang
Scott Shors
Michael Patrick O'neill
Krista Eve Peksa
Original Assignee
Cellular Bioengineering, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Bioengineering, Inc. filed Critical Cellular Bioengineering, Inc.
Priority to CA2690843A priority Critical patent/CA2690843A1/fr
Priority to EP08771435A priority patent/EP2173161A1/fr
Priority to JP2010513399A priority patent/JP2010531168A/ja
Priority to CN200880103309A priority patent/CN101815435A/zh
Publication of WO2008157664A1 publication Critical patent/WO2008157664A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
    • A01N37/04—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof polybasic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
    • A01N25/10—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/02—Acyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor

Definitions

  • TITLE METHOD FOR TREATING MICROORGANISMS AND/OR
  • This invention relates to a method for treating microorganisms and/or infectious agents. More particularly, this invention relates to a method of reducing or eliminating the reproductivity, metabolism, growth and/or pathogenicity of a microorganism and/or an infectious agent.
  • Abatement methods for removing a contaminant from a surface typically involve applying a liquid-state composition to the surface in contact with the contaminant, allowing the liquid-state composition to solidify into a solid-state matrix wherein the contaminant is sequestered by the matrix, and then removing the solid- state matrix from the surface.
  • a problem with many abatement methods is that when removing biological materials, such as microorganisms and/or infectious agents, the biological materials, although sequestered, may still be alive or active and thereby remain problematic.
  • This invention provides a solution to this problem.
  • This invention relates to a method wherein microorganisms and/or infectious agents are contacted with a polymer composition for an effective period of time to reduce or eliminate the reproductivity, metabolism, growth and/or pathogenicity of the microorganism and/or infectious agent. That is, the microorganism and/or infectious agent may be killed or inactivated as a result of treatment in accordance with the inventive method.
  • the inventive method may involve sequestering the microorganism and/or infectious agent. However, since the microorganism and/or infectious agent may be killed or inactivated with the inventive method, sequestering may not be required.
  • the inventive method comprises contacting a microorganism and/or an infectious agent with an effective amount of a polymer composition to reduce or eliminate the reproductivity, growth and/or pathogenicity of the microorganism and/or infectious agent, the polymer composition comprising water, a water-soluble film forming polymer, a chelating agent, and a surfactant.
  • the polymer may comprise repeating units derived from vinyl alcohol and/or (meth)acrylic acid (i.e., repeating units derived from acrylic acid, methacrylic acid, or a mixture thereof).
  • the invention in one embodiment, relates to a method comprising: contacting a microorganism and/or an infectious agent with an effective amount of a polymer composition to reduce or eliminate the reproductivity, metabolism, growth and/or pathogenicity of the microorganism and/or infectious agent; the polymer composition comprising water, a water-soluble film forming polymer, a chelating agent, and a surfactant; the polymer composition being characterized by the absence of an effective amount of an added biocide, viricide and/or fungicide to reduce or eliminate the reproductivity, metabolism and/or growth of the microorganism and/or infectious agent.
  • the invention in one embodiment, also relates to a method, comprising: contacting a substrate with a polymer composition comprising water, a water-soluble film forming polymer, a chelating agent, and a surfactant; drying the polymer composition to form a polymer film adhered to the substrate; separating the polymer film from the substrate; forming a biofilm on the substrate; and separating the biofilm from the substrate.
  • the biofilm may exhibit a reduction or elimination of its reproductivity, metabolism, growth and/or pathogenicity as a result of residual antimicrobial and/or bactericidal activity provided for the substrate by the polymer film.
  • This invention in one embodiment, relates to a method, comprising: contacting a substrate with a polymer composition comprising water, a water-soluble film forming polymer, a chelating agent, and a surfactant; drying the polymer composition to form a polymer film adhered to the substrate; forming a biofilm on the polymer film; and separating the biofilm from the polymer film or separating the biofilm and the polymer film from the substrate.
  • the inventive method employs the use of a polymer composition that provides an antimicrobial functionality, including sporicidal activity.
  • the polymer composition may be safe and user friendly.
  • the polymer composition may be in the form of a hydrogel.
  • the polymer composition may dry or dehydrate to a thin layer of film which may be subsequently removed by peel-off or wash-off.
  • the inventive method may be used to provide an anti-bacterial treatment for contaminated surfaces.
  • the dried or dehydrated film may be re-hydrated for DNA forensic analysis and bio-agent identification.
  • the inventive method may be used for biological decontamination applications.
  • the inventive method may be used for killing or inactivating spores, including Bacillus subtilis which is a surrogate for the anthrax bacterium B. Anthracis; and numerous pathogenic bacteria, including E. coli O157:H7, S. aureus (MRSA), which is a source of hard to treat, hospital acquired infection, and E. faecalis (VRE) and A.
  • the inventive method may be used for killing or inactivating biofilms, viruses, fungi, and the like. Surfaces remaining after the peeling or washing off of the dried or dehydrated film may be sterile and characterized by residual antimicrobial and/or bactericidal activity.
  • the polymer composition used with the inventive method may be approximately 100 times less toxic to human cells than bacteriostatic mouthwash.
  • Fig. 1 shows restriction fragment patterns for the bacteria tested in Example 20.
  • Figs. 2 and 3 show a comparison of the polymer composition from Example 1 (Fig. 2) and chlorohexidine gluconate (Fig. 3) to HeLa cells as described in Example 23.
  • Fig. 4 shows the inhibitory affect of the polymer composition from Example 1 as it leaches out of a solid material as described in Example 26.
  • Fig. 5 shows the results of the polymer from Example 1 leaching out of a solid support to protect the surrounding area against proliferation of unknown sewage bacteria as described in Example 27.
  • Fig. 6 shows the killing of bacterial spores and prevention of germinated ⁇ . subtilis bacteria as described in Example 28.
  • microorganism generally refers to any living organism that is microscopic (too small to be seen by the naked eye).
  • the term microorganism may also include living organisms such as fungi, and the like, that are technically not microscopic, due to the fact that they may be seen by the naked eye, but may have dimensions up to about 1 millimeter, and in one embodiment in the range from about 0.1 micron to about 1 millimeter, and in one embodiment in the range from about 0.1 to about 750 microns.
  • the microorganism may be unicellular or multicellular.
  • the microorganism may include bacteria, rickettsia, protozoa, fungi, or a mixture of two or more thereof.
  • the microorganism may secrete potentially lethal endotoxins when lysed or soluble exotoxins.
  • the microorganism may include microscopic plants and animals such as plankton, planarian, amoeba, and mixtures of two or more thereof.
  • the microorganisms may include anthropods such as dust mites, spider mites, and the like.
  • the microorganism may be an infectious agent.
  • infectious agent refers to a biological material that causes disease or illness to its host.
  • the infectious agent may be a pathogen.
  • the infectious agent may comprise a drug-resistant pathogen, such as a multidrug resistant Staphylococcus aureus ( MRSA).
  • MRSA multidrug resistant Staphylococcus aureus
  • the infectious agent may comprise a pathogen in its vegetative or spore form of life-cycle.
  • the infectious agent may comprise a microorganism, virus, prion, or mixture of two or more thereof.
  • contaminant or "contaminant material” are used herein to refer to a microorganism and/or infectious agent which may be treated in accordance with the inventive method.
  • spore refers to a differentiated developmental structure that is adapted for dispersion and surviving for extended periods of time in unfavorable conditions. Spores form part of the life cycle of many plants, algae, fungi and protozoan. The spores may include bacterial spores.
  • bacteria refers to unicellular microorganisms.
  • the bacteria species may be eubacteria, cyanobacteria or archaebacteria.
  • Bacteria may be prokaryotes, typically up to about one micron in length. Individual bacteria may have a wide range of shapes including spheres to rods to spirals.
  • Bacteria may be Gram- positive or Gram-negative.
  • Gram-positive bacteria possess a thick wall containing layers of peptidoglycan and teichoic acids.
  • Gram-negative bacteria have a thin cell wall consisting of a few layers of peptidoglycan surrounded by a second lipid membrane containing lipopolysaccharides and lipoproteins.
  • Some bacteria require an eukaryotic host for replication, some form spores, and some may form or participate in biofilm formation.
  • biofilm refers to an aggregation of microorganisms floating on a liquid or attached to a surface. These films may range from a few micrometers to meters in thickness and width, and may contain multiple species of bacteria, protists, archaea, and the like. Bacteria living in biofilms may display a complex arrangement of cells and protective extracellular components, forming secondary structures such as (micro)colonies, through which there may be networks of channels to enable better diffusion of nutrients.
  • the complex extracellular matrix (composed mostly of carbohydrate, proteins, deoxyribonucleic acid (DNA) but varying in composition from one biofilm to another) protects the resident bacteria from environmental changes and assaults such as dramatic changes in pH and oxygen level, dehydration, sheer stress, toxic chemicals such as oxidants (e.g. Clorox) and antibiotics.
  • Biofilm bacteria may exhibit decreased sensitivity to biocides and antibiotics, in some cases becoming 1000 fold more resistant to an antibiotic or biocide than the same type of bacteria grown in planktonic culture. Biofilms may be found widespread in the environment (e.g. hot springs), on household furnishings (e.g. shower curtains, kitchen sinks, heat exchangers), devices (e.g. filtration membranes), medical instrumentation (e.g.
  • Biofilms may be a major cause of human disease including bladder infections, colitis and conjunctivitis. These biofilms are highly resistant both to clearance by the immune system and to antibiotic treatments. Biofilms may serve as a continuous source of planktonic bacteria, which, when released from the biofilms, seed formation of new biofilms. In cases where the resident bacteria are pathogenic or infectious agents, the biofilm sloughed-off materials may seed the circulatory system and surrounding tissues with the planktonic bacteria or biofilm microcolonies and thus set off acute infections.
  • fungi refers to heterotrophic organisms often possessing a chitinous cell wall. The majority of species grow as multicellular filaments called hyphae forming a mycelium; some fungal species also grow as single cells. Sexual and asexual reproduction of the fungi is commonly via spores, often produced on specialized structures or in fruiting bodies. Some species have lost the ability to form specialized reproductive structures, and propagate solely by vegetative growth. Yeasts and molds are examples of fungi. Fungus is a eukaryotic organism that is a member of the kingdom Fungi.
  • yeast refers to a growth form of eukaryotic microorganisms classified in the kingdom Fungi, with about 1 ,500 species described in the literature. Most reproduce asexually by budding, although a few do so by binary fission. Yeasts are unicellular, although some species with yeast forms may become multicellular via cellular aggregation and be known as molds. Yeast size can vary greatly depending on the species, typically measuring 3-4 ⁇ m in diameter, although some yeasts can reach over 40 ⁇ m. Yeasts may also form biofilms which may include other microorganisms. Yeast biofilms may form in a variety of different environments, including medical implants. Yeast biofilms may be pathogenic.
  • yeast refers to species of microscopic fungi that grow in the form of multicellular filaments called hyphae.
  • microscopic fungi that grow as single cells are called yeasts.
  • a connected network of these tubular branching hyphae may have multiple, genetically identical nuclei and be considered to be a single organism.
  • virus refers to a sub-microscopic infectious agent that is unable to grow or reproduce outside a host cell.
  • Each viral particle, or viron consists of genetic material, DNA or ribonucleic acid (RNA), within a protective protein coat called a capsid.
  • the capsid shape may vary from simple geometric structures to more complex structures with tails or an envelope.
  • Viruses may infect specific cellular life forms and are grouped into animal, plant and bacterial types, according to the type of host cell that they infect.
  • prion refers to an infectious agent that is composed entirely of certain proteins. These prion proteins may exist in a normal conformation (shape) or in an altered, abnormal conformation. It is the shape of the abnormal, mis-folded prion proteins that is infectious. This misfolded shape renders the prion proteins highly resistant to inactivation via heat, pH, chemicals and enzymes. Misfolded prions cause a number of diseases in a variety of mammals, including bovine spongiform encephalopathy (BSE, also known as "mad cow disease”) in cattle and acquired Creutzfeldt-Jakob disease (CJD) in humans.
  • BSE bovine spongiform encephalopathy
  • CJD Creutzfeldt-Jakob disease
  • prion diseases affect the brain and/or other neural tissue, and all prion-caused diseases are currently untreatable and may be fatal.
  • the term prion may refer to either the theoretical unit of infection or the specific protein (e.g., PrP) that is thought to be the infective agent, whether or not it is in an infective conformation state.
  • rickettsia refers to a gram-negative, non-spore forming bacteria that depends upon the eukaryotic host cell for growth and replication. This bacteria may be referred to as being non-motile. This bacteria cannot live in artificial nutrient environments. Rickettsia are carried as parasites in a vector (e.g., fleas, ticks) to the host. Rickettsia are known to cause a number of diseases in plants and animals, such as Rocky Mountain spotted fever and Typhus. They may be referred to as being microorganisms positioned between viruses and bacteria.
  • protist refers to a diverse group of organisms comprising eukaryotes that cannot be classified in any of the other eukaryotic kingdoms as fungi, animals, or plants.
  • water-soluble refers to a material that is soluble in water at a temperature of 20 0 C to the extent of at least about 5 grams of the material per liter of water.
  • water-soluble may also refer to a material that forms an emulsion in water.
  • water-soluble film forming polymer refers to a polymer which may be dissolved in water and upon evaporation of the water forms a film or coating layer.
  • biodegradable refers to a material that degrades to form water and
  • the terms “dehydrating” and “drying” may be used interchangeably.
  • the microorganisms and/or infectious agents that may be treated in accordance with the inventive method may be referred to as contaminants.
  • the microorganism and/or infectious agent may comprise bacteria, biofilm, metazoa, or a mixture of two or more thereof.
  • the microorganism and/or infectious agent may comprise bacteria, fungus, yeast, yeast biofilm, mold, protists, or a mixture of two or more thereof.
  • the microorganism and/or infectious agent may comprise one or more spores.
  • the microorganism and/or infectious agent that may be treated may comprise a pathogen.
  • the microorganism and/or infectious agent may comprise a virus, prion, rickettsia, or a mixture of two or more thereof.
  • the microorganisms and/or infectious agents may comprise one or more biological warfare agents.
  • the microorganisms and/or infectious agents may comprise any microorganism and/or infectious agent that is encountered through contact with other humans or through contact with contaminated surfaces such as those in hospitals and the like.
  • the microorganism and/or infectious agent may comprise one or more bacterial spores, vegetative bacteria, or biofilms.
  • the microorganisms and/or infectious agents may be capable of killing or causing severe injury to mammals, particularly humans. These may include viruses, such as equine encephalomyelitis and smallpox, the coronavirus responsible for Severe Acute Respiratory Syndrome (SARS), herpes virus, hepatitis virus, and the like.
  • viruses such as equine encephalomyelitis and smallpox, the coronavirus responsible for Severe Acute Respiratory Syndrome (SARS), herpes virus, hepatitis virus, and the like.
  • SARS Se
  • bacteria such as those which cause plague (Yersina pestis), anthrax (Bacillus anthracis), tularemia (Francisella tularensis), wound or lung infections (e.g. Staphylococcus aureus (Including multi-drug-resistant S. aureus MRSA, Pseudomonas aeruginosa (potential biofilm former)), contaminate foods (Escherichia coli (E. coli 0157-H7JJ, or Enterococcus faecalis, including Vancomycin resistant Enterococcus (VRE).
  • Staphylococcus aureus Including multi-drug-resistant S. aureus MRSA, Pseudomonas aeruginosa (potential biofilm former)
  • contaminate foods Escherichia coli (E. coli 0157-H7JJ, or Enterococcus faecalis, including Vancomycin resistant Enterococcus (VRE).
  • the microorganisms and/or infectious agents may include fungi, which, among others include the dimorphic fungus Coccidioides which may cause coccidioidomycosis, Candida albicans which may cause the wide-spread Candidiasis (that can be life threatening, particularly in an immunocompromised patient) or Aspergillus which may cause a wide spectrum of human diseases.
  • the microorganisms and/or infectious agents may include toxic products produced by such microorganisms; for example, the botulism toxin (BT) expressed by the Clostridium botulinium bacterium.
  • BT botulism toxin
  • the microorganisms and/or infectious agents may include those responsible for the common cold (rhinoviruses), warts and predisposition to cancer (pappilloma virus), influenza (orthomyxoviruses), skin abscesses, toxic shock syndrome (Staphylococcus aureus), bacterial pneumonia (Streptococcus pneumoniae), stomach upsets (Escherichia coli, Salmonella), and the like.
  • the microorganisms and/or infectious agents that may be treated may comprise one or more of Escherichia coli, Staphylococcus epidermidis, Staphylococcus aureus, Burkholderia cepacia, Bacillus subtilis, Enterococcus faecalis, Pseudomonas aeruginosa, Streptococcus pyogenes, Acinetobacter baumannii, or Candida albicans.
  • These microorganisms may be antibiotic/drug resistant such as S. aureus MRSA, MDR A. baumannii and VRE E. faecalis), and/or may be biofilm-forming organisms ( e.g. Pseudomonas aeruginosa), and/or may be spore-forming organisms (e.g. S. subtilis, B. anthracis, and Clostridium spp.)
  • the microorganisms and/or infectious agents that may be treated may comprise one or more of Escherichia coli, Escherichia coli 0157-H7, Staphylococcus epidermidis, Staphylococcus epidermidis biofilms, Staphylococcus aureus, Staphylococcus aureus MRSA, Burkholderia cepacia, Bacillus subtilis, Enterococcus faecalis, Enterococcus faecalis-VRE, Pseudomonas aeruginosa, Pseudomonas aeruginosa biofilms, Streptococcus pyogenes, Acinetobacter baumannii, Candida albicans, or Candida albicans biofilms.
  • the polymer composition may comprise water, at least one water-soluble film forming polymer, at least one chelating agent, and at least one surfactant.
  • the polymer may comprise repeating units derived from vinyl alcohol and/or (meth)acrylic acid.
  • the polymer may comprise polyvinyl alcohol, a copolymer of vinyl alcohol, or a mixture thereof.
  • copolymer may be used herein to refer to a polymer with two or more different repeating units including copolymers, terpolymers, and the like.
  • the polymer may comprise an atactic polyvinyl alcohol. These polymers may have a semicrystalline character and a strong tendency to exhibit both inter- molecular and intra-molecular hydrogen bonds.
  • the polymer may comprise repeating units represented by the formula -CH 2 - CH(OH)- and repeating units represented by the formula -CH 2 -CH(OCOR)- wherein R is an alkyl group.
  • the alkyl group may contain from 1 to about 6 carbon atoms, and in one embodiment from 1 to about 2 carbon atoms.
  • the number of repeating units represented by the formula -CH 2 -CH(OCOR)- may be in the range from about 0.5% to about 25% of the repeating units in the polymer, and in one embodiment from about 2 to about 15% of the repeating units.
  • the ester groups may be substituted by acetaldehyde or butyraldehyde acetals.
  • the polymer may comprise a polyvinyl alcohol/vinyl acetate) structure.
  • the polymer may be in the form of a vinyl alcohol copolymer which also contains hydroxyl groups in the form of 1 ,2-glycols, such as copolymer units derived from 1 ,2- dihydroxyethylene.
  • the copolymer may contain up to about 20 mole % of such units, and in one embodiment up to about 10 mole % of such units.
  • the polymer may comprise a copolymer containing repeating units derived from vinyl alcohol and/or (meth)acrylic acid, and repeating units derived from one or more of vinyl acetate, ethylene, propylene, acrylic acid, methacrylic acid, acrylamide, methacrylamide, dimethacrylamide, hydroxyethylmethacrylate, methyl methacrylate, methyl acrylate, ethyl acrylate, vinyl pyrrolidone, hydroxyethylacrylate, hydroxymethylcellulose, hydroxethylcellulose, allyl alcohol, and the like.
  • the copolymer may contain up to about 50 mole % of repeating units other than those of vinyl alcohol, and in one embodiment from about 1 to about 20 mole % of such repeating units other than vinyl alcohol.
  • the polymer may have a hydrolysis level in the range from about 70% to about 100%, and in one embodiment from about 70% to about 99.3%, and in one embodiment in the range from 70% to about 95%, and in one embodiment from about 70% to about 90%, and in one embodiment from about 87% to about 89%.
  • the polymer may comprise repeating units derived from one or more
  • (meth)acrylic acids i.e. acrylic acid and/or methacrylic acid. These may include linear, crosslinked, lightly crosslinked, neutralized and/or partially neutralized forms of the polymer. These may be available under the name Polyacrylic Acid 5100 from Hampton Research; Poly(acrylic acid), which is a partial sodium salt, lightly crosslinked polymer available from Sigma Aldrich; Poly(acrylic acid) from Polysciences, lnc (MW ⁇ 90000 g/mol); and Poly(Acrylic Acid) from Polysciences lnc (MW: ⁇ 100000 g/mol).
  • Polymethacrylic acids that may be used may include those available under tradenames Poly(methacrylic acid solution salt) from Sigma Aldrich (MW: -429,000 to 549,000 g/mol), and Poly Methacrylic Acid (25087-26-7) from Polysciences lnc (MW: -100,000 g/mol).
  • the polymer may have a weight average molecular weight of at least about 5,000 g/mol.
  • the polymer may have a weight average molecular weight of up to about 2,000,000 g/mol.
  • the polymer may have a weight average molecular weight in the range from about 5000 to about 2,000,000, and in one embodiment in the range from about 10,000 to about 1 ,000,000 g/mol, and in one embodiment from about 10,000 to about 600,000, and in one embodiment from about 10,000 g/mol to about 250,000 g/mol, and in one embodiment from about 10,000 g/mol to about 190,000 g/mol, and in one embodiment in the range from about 10,000 to about 150,000 g/mole, and in one embodiment in the range from about 50,000 to about 150,000 gl/mole, and in one embodiment in the range from about 85,000 to about 125,000 g/mole.
  • the concentration of the polymer in the polymer composition may be in the range from about 0.5 to about 50% by weight, and in one embodiment from about 1 to about 25% by weight, and in one embodiment in the range from about 1 to about 20% by weight, and in one embodiment in the range from about 2 to about 10% by weight.
  • the polymer composition may have a concentration of water (before drying or dehydrating) in the range from about 40 to about 99% by weight, and in one embodiment from about 60 to about 95% by weight.
  • the water may be derived from any source.
  • the water may comprise deionized or distilled water.
  • the water may comprise tap water.
  • the water may comprise sterile nanopure water.
  • the chelating agent, or chelant may comprise one or more organic or inorganic compounds that contain two or more electron donor atoms that form coordinate bonds to metal ions or other charged particles. After the first such coordinate bond, each successive donor atom that binds may create a ring containing the metal or charged particle.
  • the structural aspects of a chelate may comprise coordinate bonds between a metal or charged particle, which may serve as an electron acceptor, and two or more atoms in the molecule of the chelating agent, or ligand, which may serve as the electron donors.
  • the chelating agent may be bidentate, tridentate, tetradentate, pentadentate, and the like, according to whether it contains two, three, four, five or more donor atoms capable of simultaneously complexing with the metal ion or charged particle.
  • the chelating agent may comprise an organic compound that contains a hydrocarbon linkage and two or more functional groups.
  • the same or different functional groups may be used in a single chelating agent.
  • the functional groups may comprise phosphate and/or phosphonate groups.
  • the alkyl groups may contain from 1 to about 10 carbon atoms, and in one embodiment from 1 to about 4 carbon atoms.
  • the alkylene groups may contain from 2 to about 10 carbon atoms, and in one embodiment from 2 to about 4 carbon atoms.
  • the chelating agent may comprise one or more of ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), prussian blue, citric acid, peptides, amino acids including short chain amino acids, aminopolycarboxylic acids, gluconic acid, glucoheptonic acid, organophosphonates, bisphosphonates such as pamidronate, inorganic polyphosphates, and the like.
  • Salts of one or more of the foregoing chelating agents may be used. These may include sodium, calcium and/or zinc salts of the foregoing.
  • the sodium, calcium and/or zinc salts of DTPA may be used. Salts of the foregoing chelating agents may be formed when neutralizing the agent with, for example, sodium hydroxide. Mixtures of two or more of any of the foregoing may be used.
  • the concentration of the chelating agent in the polymer composition may be in the range from about 0.1 to about 5% by weight, and in one embodiment from about 0.5 to about 2% by weight.
  • the surfactant may comprise one or more ionic and/or nonionic compounds having a hydrophilic lipophilic balance (HLB) in the range of zero to about 18 in Griffin's system, and in one embodiment from about 0.01 to about 18.
  • the ionic compounds may be cationic or amphoteric compounds. Examples may include those disclosed in McCutcheons Surfactants and Detergents, 1998, North American & International Edition. Pages 1-235 of the North American Edition and pages 1- 199 of the International Edition are incorporated herein by reference for their disclosure of such surfactants.
  • the surfactants that may be used may comprise one or more polysiloxanes, alkanolamines, alkylarylsulfonates, amine oxides, poly(oxyalkylene) compounds, including block copolymers comprising alkylene oxide repeat units, carboxylated alcohol ethoxylates, ethoxylated alcohols, ethoxylated alkyl phenols, ethoxylated amines and amides, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty esters, fatty acid amides, glycerol esters, glycol esters, sorbitan esters, imidazoline derivatives, lecithin and derivatives, lignin and derivatives, monoglycerides and derivatives, olefin sulfonates, phosphate esters and derivatives, propoxylated and ethoxylated fatty acids or alcohols or alkyl phenols, sorbitan derivatives,
  • the surfactant may comprise a centrimonium cation, a hexadecyltrimethylammonium cation (HDTMA), or a mixture thereof.
  • the surfactant may comprise sodium dodecyl sulfate (SDS), sodium lauryl sulfate, cetyltrimethylammonium bromide, cetyltrimethyl ammonium chloride, hexadecyl trimethyl ammonium bromide, hexadecyl trimethyl ammonium chloride, or a mixture of two or more thereof.
  • the concentration of the surfactant in the polymer composition may be in the range from about 0.05 to about 10% by weight of the composition, and in one embodiment in the range from about 0.1 to about 5% by weight, and in one embodiment from about 0.1 to about 2% by weight.
  • the polymer composition may further comprise one or more crosslinkers, soaps, detergents, thixotropic additives, pseudoplastic additives, rheology modifiers, anti-settling agents, anti-sagging agents, leveling agents, defoamers, colorants, organic solvents, plasticizers, viscosity stabilizers, biocides, viricides, fungicides, chemical warfare agent neutralizers, humectants, or a mixture of two or more thereof.
  • crosslinkers soaps, detergents, thixotropic additives, pseudoplastic additives, rheology modifiers, anti-settling agents, anti-sagging agents, leveling agents, defoamers, colorants, organic solvents, plasticizers, viscosity stabilizers, biocides, viricides, fungicides, chemical warfare agent neutralizers, humectants, or a mixture of two or more thereof.
  • the crosslinker may comprise sodium tertraborate, glyoxal, Sunrez 700 (a product of Sequa Chemicals identified as a cyclic urea/glyoxal/polyol condensate), Bacote-20 (a product of Hopton Technology identified as a stabilized ammonium zirconium carbonate), polycup-172 (a product of Hercules, Inc. identified as a polyamide-epichlorohydrin resin), or a mixture of two or more thereof.
  • the soap may comprise a surfactant that may be used with water for washing or cleaning.
  • the soap may be a salt of a fatty acid.
  • the soap may be made by reacting a fat with an alkali such as sodium hydroxide, sodium carbonate or potassium hydroxide. The reaction may be saponification wherein the alkali and water hydrolyze the fat to convert it into free glycerol/glycerin and fatty acid salt.
  • the detergent may comprise a composition that may be used to assist cleaning.
  • the detergent may comprise the combination of one or more soaps, surfactants, abrasives, pH modifiers, water softeners, oxidants, non-surfactant materials that keep contaminants in suspension, enzymes, foam stabilizers, brighteners, fabric softeners, perfumes, corrosion inhibitors, preservatives, and the like.
  • the thixotropic additive may comprise one or more compounds that enables the polymer composition to thicken or stiffen in a relatively short period of time on standing at rest but, upon agitation or manipulation (e.g., brushing, rolling, spraying) to flow freely.
  • the thixotropic additive may comprise fumed silica, treated fumed silica, clay, hectorite clay, organically modified hectorite clay, thixotropic polymers, pseudoplastic polymers, polyurethane, polyhydroxycarboxylic acid amides, modified urea, urea modified polyurethane, or a mixture of two or more thereof.
  • a thixotropic additive that may be used is Byk-420 which is a product of Chemie identified as a modified urea.
  • the leveling agent may comprise polysiloxane, dimethylpolysiloxane, polyether modified dimethylpolysiloxane, polyester modified dimethylpolysiloxane, polymethylalkysiloxane, aralkyl modified polymethylalkylsiloxane, alcohol alkoxylates, polyacrylates, polymeric fluorosurfactants, fluoro modified polyacrylates, or a mixture of two or more thereof.
  • the colorant may comprise one or more dyes, pigments, and the like. These may include Blue Food Color Formula # 773389 from McCormick and Company Inc., and/or Spectrazurine Blue FND-C LIQ from Spectra Colors Corp.
  • the colorant may comprise one or more dyes that become fluorescent upon drying or in response to a change in pH.
  • the organic solvent may comprise one or more alcohols, for example, methanol, ethanol, propanol, butanol, one or more ketones, for example, acetone, one or more acetates, for example, methyl acetate, or a mixture of two or more thereof.
  • alcohols for example, methanol, ethanol, propanol, butanol
  • ketones for example, acetone
  • acetates for example, methyl acetate, or a mixture of two or more thereof.
  • the plasticizer may comprise ethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, butane diol, polybutylene glycol, glycerine, or a mixture of two or more thereof.
  • the viscosity stabilizer may comprise a mono or multifunctional hydroxyl compound. These may include methanol, ethanol, propanol, butanol, ethylene glycol, polyethylene glycol, propylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, butane diol, polybutylene glycol, glycerine, or a mixture of two or more thereof.
  • the biocide, viricide or fungicide may have the capability of killing or inactivating common biological contaminates.
  • the biocide, viricide or fungicide may comprise sodium hypochlorite, potassium hypochlorite, pH-amended sodium hypochlorite, quaternary ammonium chloride, pH-amended bleach (Clorox®), CASCADTM surface decontamination foam (AllenVanguard), DeconGreen (Edgewood Chemical Biological Center), DioxiGuard (Frontier Pharmaceutical), EasyDecon 200 (Envirofoam Technologies), Exterm-6 (ClorDiSys Solutions), Hl- Clean 605 (Howard Industries), HM-4100 (Biosafe) KlearWater (Disinfection Technology), Peridox (Clean Earth Technologies) Selectrocide (BioProcess Associates), EasyDECONTM 200 decontamination solution or a mixture of two or more thereof.
  • the biocide may comprise Kathon LX (a product of Rohm and Hass Company comprising 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4- isothiazolin-3-one) or Dowacil 75 (a product of Dow Chemical comprising 1-(3- chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride described as being useful as a preservative for antimicrobial protection).
  • Kathon LX a product of Rohm and Hass Company comprising 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4- isothiazolin-3-one
  • Dowacil 75 a product of Dow Chemical comprising 1-(3- chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride described as being useful as a preservative for antimicrobial protection.
  • the polymer composition used with the inventive method may be characterized by the absence of an effective amount of an added biocide, viricide and/or fungicide to reduce or eliminate the reproductivity, metabolism, growth and/or pathogenicity of the microorganism and/or infectious agent being treated.
  • the chemical warfare agent neutralizers may comprise potassium permanganate, potassium peroxydisulfate, potassium peroxymonosulfate (Virkon S®), potassium molybdate, hydrogen peroxide, chloroisocyanuric acid salt, sodium hypochlorite, potassium hypochlorite, pH-amended sodium hypochlorite, hydrogen peroxide, oxidants, nucleophiles, hydroxide ions, catalytic enzymes, organophosphorous acid anhydrolase, o-iodosobenzoate, iodoxybenzoate, perborate, peracetic acid, m-chloroperoxybenzoic acid, magnesium monoperoxyphthalate, benzoyl peroxide, hydroperoxy carbonate ions, polyoxymetalates, quaternary ammonium complexes, Sandia Foam (Sandia National Laboratories), EasyDECONTM 200 Decontamination Solution, Modec's Decon Formula (Modec, Inc.) or a mixture of two or more
  • the humectant may comprise polyacrylic acid, polyacrylic acid salt, an acrylic acid copolymer, a polyacrylic acid salt copolymer, or a mixture of two or more thereof.
  • the concentration of each of the foregoing additives in the polymer composition may be up to about 25% by weight, and in one embodiment up to about 10% by weight, and in one embodiment up to about 5% by weight, and in one embodiment up to about 2% by weight, and in one embodiment up to about 1% by weight.
  • the polymer composition may have a broad range of viscosities and rheological properties which may allow the polymer composition to diffuse into a substrate (i.e., clean or contaminated substrate) for a relatively deep cleaning, allow for a variety of application methods including application via brush, roller or spray equipment, and to allow for a thick enough wet film on non-horizontal surfaces to result in a dry film with sufficient strength to allow for removal by peeling or stripping the film.
  • the surfactant may be used to control or enhance these rheological properties.
  • the Brookfield Viscosity of the polymer composition may be in the range from about 100 to about 500,000 centipoise, and in one embodiment in the range from about 200 to about 200,000 centipoise measured at the rpm and spindle appropriate for the sample in the range of 0.3 - 60 rpm and spindles 1-4 at 25 0 C.
  • the polymer composition may have a sufficient viscosity to permit it to form a wet film on a horizontal and/or a non-horizontal substrate that upon drying or dehydrating forms a solid matrix or film which may be subsequently stripped off the substrate or washed off the substrate.
  • the polymer composition may be applied to the microorganism and/or infectious agent and allowed to dry.
  • the polymer composition upon drying may form a solid matrix that sequesters the microorganism and/or infectious agent.
  • the microorganism and/or infectious agent may be positioned on a substrate, and the inventive method may comprise applying the polymer composition to the substrate in contact with the microorganism and/or infectious agent, drying the polymer composition to form a film, and removing the film from the substrate.
  • the film may be peeled off the substrate.
  • the film may be removed by applying a composition comprising water (e.g., a cleaning solution comprising soap or detergent and water) to the film then removing the film from the substrate by conventional techniques such as washing or scrubbing.
  • the polymer composition may be applied to the substrate using conventional coating techniques, for example, brushing, rolling, spraying, spreading, dipping, smearing, and the like.
  • the substrate may comprise a contaminated substrate wherein the film is applied to the contaminated substrate and the contaminant material is taken up by the film.
  • the film may be applied to a clean substrate which is subjected to subsequent contamination wherein the contaminant material is deposited on or in the film and subsequently removed with the film.
  • the polymer composition may be dehydrated or dried to form the film. Dehydration or drying may be enhanced using fans, dehumidifiers, a heat source, or a combination thereof.
  • the contaminant material may be killed or rendered harmless.
  • the contaminant material may be taken up, sorbed and/or complexed by or with the polymer composition or components of the polymer composition.
  • the contaminant material may be adhered to the surface of the film.
  • the film combined with the contaminant material may be separated from the substrate leaving a non-contaminated surface or a surface with a reduced level of contamination.
  • the film may be stripped or peeled from the substrate.
  • the film may be washed off the substrate using a composition comprising water, for example, a cleaning solution comprising water and soap or detergent.
  • the film may not require removal from the substrate in order to reduce or eliminate the reproductively, metabolism and/or growth of the microorganism and/or infectious agent.
  • the polymer composition may be applied to a substrate and when the polymer composition is dried or dehydrated, resulting in the formation of a film, it may encapsulate, entrap, solublize or emulsify the microorganism and/or infectious agent as well as reduce or eliminate the ability of the microorganism and/or infectious agent to reproduce, metabolize and/or grow.
  • the dried or dehydrated film may have a concentration of water in the range up to about 25% by weight, and in one embodiment in the range from about 1 to about 15% by weight. When the polymer composition is dehydrated, it may be referred to as a hydrogel.
  • the film may be a strippable or peelable film.
  • the film may have a thickness and tensile strength sufficient to allow for it to be stripped or peeled from a substrate.
  • the film thickness may be in the range up to about 50 mils, and in one embodiment from about 0.01 to about 50 mils, and in one embodiment from about 0.01 to about 25 mils, and in one embodiment from about 0.05 to about 5 mils.
  • the film may be removed from a substrate using conventional washing and scrubbing techniques.
  • An advantage of the polymer composition is that it may be applied wet to a substrate and then dried or dehydrated to form a solid matrix such as a film. In one embodiment, the formation of the solid matrix does not involve a cross-linking reaction. Thus, the use of a two-component system involving the use of a cross- linking agent may be avoided. This also provides the advantage of being able to rehydrate the polymer film and subject it to analysis as discussed below.
  • the polymer composition may be delivered in a rehydratable form that may not require a commercial process to rehydrate. Examples may include a powder that can be rehydrated for single use applications. Water may be added with minimal or no agitation. Sodium or potassium neutralized poly(meth)acrylic acids may be useful for direct rehydration for gels or solutions that can be prepared from a dry powder before use.
  • the polymer composition in at least one embodiment, may exhibit about 100 times lower toxicity to human HeLa cells in culture than chlorohexidine gluconate (a commonly used bacteriostatic mouth wash).
  • the polymer composition may be applied to the substrate using a laminate structure.
  • the laminate structure may comprise a layer of the film overlying part or all of one side of a release liner.
  • the film layer may be positioned between two release liners.
  • the film layer may be formed by coating one side of the release liner with the polymer composition using conventional techniques (e.g., brushing, roller coating, spraying, and the like) and then dehydrating or drying the polymer composition to form the film layer. If the laminate structure comprises a second release liner, the second release liner may then be placed over the film layer on the side opposite the first release liner.
  • the film layer may have a thickness in the range from about 1 to about 500 mils, and in one embodiment from about 5 to about 100 mils.
  • the release liner(s) may comprise a backing liner with a release coating layer applied to the backing liner.
  • the release coating layer contacts the film layer and is provided to facilitate removal of the release liner from the film layer.
  • the backing liner may be made of paper, cloth, polymer film, or a combination thereof.
  • the release coating may comprise any release coating known in the art. These may include silicone release coatings such as polyorganosiloxanes including polydimethylsiloxanes.
  • the laminate structure may be provided in roll form.
  • the film layer may be applied to a substrate by contacting the substrate with the film layer, and then removing the release liner from the film layer.
  • the film layer may be sufficiently tacky to adhere to the substrate.
  • the laminate structure may be provided in the form of flat sheets.
  • the film layer may be applied to a substrate by peeling off one of the release liners from the laminate structure, contacting the substrate with the film layer, positioning the film layer on the substrate, and then removing the other release liner from the film layer.
  • the substrates that may be treated with the inventive method may include human skin and wounds, as well as cloth, paper, wood, metal, glass, concrete, painted surfaces, plastic surfaces, and the like.
  • the substrates may include seeds that require surface sterilization or disinfection.
  • the substrate may comprise a porous, permeable or non-porous material.
  • the substrate may comprise horizontally aligned non-porous substrates such as floors, counter tops, table tops, exercise medical equipment, gurneys, heart stress test room surfaces, toilet seats, as well as complex three dimensional structures such as faucets, tools and other types of equipment or infrastructure and the like.
  • the substrate may comprise non- horizontally aligned surfaces such as walls, doors, windows, and the like.
  • the substrates may include tile, Formica, porcelain, chrome, stainless steel, glass, sealed grout, unsealed grout, rubber, leather, plastic, painted surfaces, concrete, wood, reactors, storage vessels, and the like.
  • the substrates may include surgical equipment made of metal, glass, plastic, and the like, as well as instrumentation.
  • the inventive method may be used to decontaminate buildings, medical facilities, articles of manufacture, buildings and infrastructure intended for demolition, military assets, airplanes, as well as the interiors and exteriors of military or civilian ships.
  • the inventive method may be used to sterilize, decontaminate or disinfect biological laboratories and biological warfare research facilities from contamination ranging from ordinary wide spread microorganisms and/or infectious agents, such as common bacterial and fungal contamination, to the more dangerous multi-drug resistant pathogens, as well as the extremely hazardous materials, such as anthrax, HIV and Ebola viruses.
  • the film (wet or dry) may be separated (i.e., wiped, washed or peeled) from the substrate and dispersed or dissolved in a liquid such as water and then analyzed for the presence of microorganisms and/or infectious agents. This may involve rehydrating the film.
  • the peeled or separated film may be subjected to polymerase chain reaction (PCR) analysis, and subsequent nucleotide sequence analysis and/or amino acid sequence analysis.
  • PCR polymerase chain reaction
  • the DNA may be extracted and subjected to forensic analysis via PCR amplification with ribosomal DNA primers, and the product thereof may then be subjected to restriction fragment length polymorphism (RFLP), DNA cloning and/or DNA sequencing. This may be used to identify the particular microorganism and/or infectious agent that was killed or inactivated by and contained within the film.
  • RFLP restriction fragment length polymorphism
  • the microorganism and/or infectious agent may be dispersed in a liquid medium such as water, and the process may comprise adding the polymer composition to the liquid medium.
  • the polymer composition may be added at a sufficient concentration and for an effective period of time to reduce or eliminate the reproductivity, metabolism, growth and/or pathogenicity of the microorganism and/or infectious agent.
  • the killing or inhibiting affect of the polymer composition may be improved by drying or dehydrating the polymer composition while in contact with the microorganisms and/or infectious agents.
  • the microorganisms and/or infectious agents contacted by the polymer composition may have their reproductivity, metabolism, growth and/or pathogenicity reduced or eliminated by, during or after the drying or dehydrating process.
  • the polymer composition may be applied to a substrate to form a film and the microorganism and/or infectious agent may subsequently contact the polymer composition.
  • the polymer composition may be wet or dry when contacted by the microorganism and/or infectious agent.
  • the film and the microorganism and/or infectious agent may then be removed from the substrate.
  • the film and the microorganism and/or infectious agent may be removed by peeling the film off the substrate.
  • the film and the microorganism and/or infectious agent may be removed by applying a composition comprising water (e.g., a cleaning solution comprising soap or detergent and water) to the film and the microorganism and/or infectious agent, and then removing the film and the microorganism and/or infectious agent from the substrate using conventional techniques such as washing or scrubbing.
  • a composition comprising water (e.g., a cleaning solution comprising soap or detergent and water)
  • microorganisms and/or infectious agents near the microorganisms and/or infectious agents contacted by the polymer composition may have their reproductivity, metabolism, growth and/or pathogenicity reduced or eliminated.
  • the inventive method may involve contacting or stripping the substrate with the polymer and drying the polymer composition to form a polymer film, trapping the microorganism and/or infectious agent within the dried polymer film, and separating the dried polymer film from the substrate.
  • the microorganism and/or infectious agent may be separated from the substrate with the film.
  • the surface left behind may be devoid of the microorganisms and/or infectious agents and left sterile.
  • the separated polymer film may be subjected to PCR/RFLP analysis for identification of the microorganism and/or infectious agent.
  • the polymer film may be re-hydrated, and the polymer film and now-inactivated microorganism and/or infectious agent may be removed using traditional methods, for example, soap and water.
  • Examples 1-6 provide examples of preparation of the polymer composition that may be used with the inventive method. In these examples, as well as throughout the text, unless otherwise indicated, all parts and percentages are by weight.
  • a jacketed one-liter reactor equipped with a thermocouple, condenser and stir motor is charged with 677.2 grams of distilled water, 8.0 grams of diethylenetriaminepentaacetic acid (DTPA), 8.0 grams of sodium dodecyl sulfate (SDS), 7.9 grams of 10 N sodium hydroxide, 4.0 grams of Byk-028 (product of BYK Chemie identified as a mixture of foam destroying polysiloxanes and hydrophobic solids in polyglycol).
  • DTPA diethylenetriaminepentaacetic acid
  • SDS sodium dodecyl sulfate
  • 10 N sodium hydroxide 4.0 grams of Byk-028 (product of BYK Chemie identified as a mixture of foam destroying polysiloxanes and hydrophobic solids in polyglycol).
  • Byk-028 product of BYK Chemie identified as a mixture of foam destroying polysiloxanes and hydrophobic solids in polyglycol.
  • a jacketed one-liter reactor equipped with a thermocouple, condenser and stir motor is charged with 677.2 grams of distilled water, 8.0 grams of DTPA, 8.0 grams of SDS, 7.9 grams of 10 N sodium hydroxide, 4.0 grams of Byk-028, and 4.0 grams of Byk-080A (product of BYK Chemie identified as hydrophobic solids and polysiloxanes).
  • the resulting aqueous composition is agitated until the salts are dissolved followed by the addition of 123.0 grams of Celvol 523.
  • the mixture is heated to 85 0 C and held for 30 minutes, then cooled to 7O 0 C.
  • the mixture is then cooled to 45 0 C while adding 49.0 grams of ethanol to the mixture.
  • BYK-420 12.0 grams of BYK-420 are added drop wise to the mixture with stirring over a period of 1 hour. 4.0 grams of BYK-345, 1.0 grams of Dowicil 75, 2.0 grams of blue food coloring, and 83.0 grams of distilled water are added. The resulting polymer composition has pH of 6.81. This polymer composition may be referred to as an aqueous polymer composition.
  • a jacketed one-liter reactor equipped with a thermocouple, condenser and stir motor is charged with 1708.3 grams of distilled water, 8.5 grams of DTPA, 8.5 grams of SDS, 8.5 grams of 10 N sodium hydroxide, 4.2 grams of Byk-028 and 4.2 grams of Byk-080A.
  • the resulting aqueous composition is agitated until the salts are dissolved followed by the addition of 125.0 grams of Celvol 523.
  • the mixture is heated to 85 0 C and held for 30 minutes, then cooled to 7O 0 C.
  • the mixture is then cooled to 45 0 C while adding 50.0 grams of ethanol to the mixture. 12.5 grams of BYK-420 are added drop wise to the mixture with stirring over a period of 1 hour.
  • Example 4 A jacketed one-liter reactor equipped with a thermocouple, condenser and stir motor is charged with 645.5 grams of distilled water, 8.0 grams of DTPA, 28.5 grams of Stanfax 1025 (a product of Para Chem, Chemidex LLC, identified as sodium lauryl sulfate), 4.0 grams of 46% sodium hydroxide, 4.0 grams of Byk-028, and 4.0 grams of Byk-080A. The resulting aqueous composition is agitated until the salts are dissolved followed by the addition of 123.0 grams of Celvol 523. The mixture is heated to 85 0 C and held for 30 minutes, then cooled to 7O 0 C.
  • the mixture is cooled to 45 0 C while adding 46.5 grams of ethanol SDA 3C 190PF (denatured alcohol) to the mixture.
  • 12.5 grams of BYK-420 are added drop wise to the mixture with stirring over a period of 1 hour.
  • 4.0 grams of BYK-345, 0.05 gram of Spectrazurine Blue FGND-C LIQ (supplied by Spectra Color Corp.), and 39.0 grams of distilled water are added.
  • a premix of 1.5 grams of Dowicil 75 and 63.0 grams of distilled water are added.
  • 200.0 grams of the resulting polymer composition are added to 800.0 grams of distilled water to provide a polymer composition that is diluted to 20% by weight.
  • the resulting polymer composition has pH of 6.13.
  • the diluted polymer composition may be referred to as being diluted to 20% by weight.
  • a jacketed one-liter reactor equipped with a thermocouple, condenser and stir motor is charged with 645.5 grams of distilled water, 8.0 grams of DTPA, 28.5 grams of (Stanfax 1025), 4.0 grams of 46% sodium hydroxide, 4.0 grams of Byk-028, and 4.0 grams of Byk-080A.
  • the resulting aqueous composition is agitated until the salts are dissolved followed by the addition of 123.0 grams of Celvol 523.
  • the mixture is heated to 85 0 C and held for 30 minutes, then cooled to 7O 0 C.
  • the mixture is cooled to 45 0 C while adding 46.5 grams of ethanol SDA 3C 190PF to the mixture.
  • Example 6 A jacketed one-liter reactor equipped with a thermocouple, condenser and stir motor is charged with 645.5 grams of distilled water, 8.0 grams of DTPA, 28.5 grams of Stanfax 1025, 4.0 grams of 46% sodium hydroxide, 4.0 grams of Byk-028, and 4.0 grams of Byk-080A. The resulting aqueous composition is agitated until the salts are dissolved followed by the addition of 123.0 grams of Celvol 523. The mixture is heated to 85 0 C and held for 30 minutes, then cooled to 7O 0 C. The mixture is cooled to 45 0 C while adding 46.5 grams of ethanol SDA 3C 190PF to the mixture.
  • the polymer composition from Example 3 is diluted with sterile nanopure water to prepare the following diluted polymer compositions: 50%, 25%, 10%, 0%.
  • 250 ⁇ l of the diluted polymer composition are mixed with or covered on 10 ⁇ l solutions of various bacteria ( ⁇ 10 6 ).
  • Samples of the resulting mixtures are covered and sealed for 12 or 20 hours at room temperature. Additional samples of the resulting mixtures are left open for 12 or 20 hours at room temperature in a sterile hood.
  • 1 ml of Luria Broth (LB) or Nutrient Broth (NB) is added to each sample. The samples are incubated at 37°C without shaking for 24 or 37 hours. Three 200 ⁇ l portions of each sample are transferred to a 96-well plate. Absorbance is measured at 595 nm using a 96-well plate reader.
  • Example 3 is sufficient to completely inhibit the growth of each of the species tested.
  • the minimum inhibitory concentration (MIC) for the bacteria species identified in the table below is determined using the polymer composition from Example 3.
  • MIC is the lowest concentration of an antibiotic agent that inhibits spectrophotomethcally measurable bacterial growth.
  • the polymer composition from Example 3 is diluted with sterile nanopure water to prepare a 25% polymer composition.
  • the following diluted polymer compositions are obtained by twofold series dilution with broth as diluent: 12.5%, 6.25%, 3.1%, 1.6%, 0.8%, 0.4%, 0.2%, and 0%. With each of these, the polymer composition from Example 3 is diluted to provide for the desired diluted polymer composition.
  • the polymer composition diluted to 6.25% contains 6.25% of the product from Example 3.
  • Inoculum suspensions for bacteria identified in the table are obtained by inoculating 20 ⁇ l solutions of the bacteria ( ⁇ 2*10 6 ) overnight culture to 1 ml fresh broth medium.
  • Test samples are prepared by mixing 100 ⁇ l of bacterium inoculum suspensions with 100 ⁇ l of the diluted polymer compositions. The results are as follows:
  • the MIC against S. epidermidis and P. aeruginosa to develop a biofilm is determined.
  • the polymer composition from Example 3 is diluted with sterile nanopure water to prepare a 50% polymer composition.
  • the following diluted polymer compositions are obtained by twofold series dilution with broth as diluent: 25%, 12.5%, 6.25%, 3.1 %, 1.6%, 0.8%, 0.4%, 0.2%, and 0%.
  • Bacteria inoculum suspensions are obtained by inoculating 20 ⁇ l solutions of the bacteria ( ⁇ 2*10 6 ) overnight culture to 1 ml fresh broth medium.
  • Test samples are prepared by mixing 500 ⁇ l of bacterium inoculum suspensions with 500 ⁇ l of the diluted polymer compositions. The samples are incubated stationary at 37°C for 24 hours. The results are indicated below.
  • the polymer composition from Example 3 is used to kill or inhibit a pre-formed biofilm of individual bacterial species.
  • the polymer composition from Example 3 is diluted with sterile nanopure water to prepare the following diluted polymer compositions: 50%, 25%, 10%, 0%.
  • a preformed biofilm is prepared by inoculating 1 ml of a growth medium in wells with 10 ⁇ l of an overnight bacterial growth ( ⁇ 10 6 ) and incubating the mixture at 37 0 C for 24 hours. The biofilm forms on the bottom and the sides of the wells. The growth medium is removed.
  • 0.2 ml or 0.3 ml of diluted polymer compositions are pipetted into the wells containing S. epidermidis biofilms or P.
  • aeruginosa biofilms aeruginosa biofilms, and maintained at room temperature in a sterile hood until dry. This results in the formation of polymer films in each of the wells.
  • Half of the films are peeled off and transferred to sterile empty wells, with the other half left in situ.
  • 1 ml of fresh growth medium is added to each well and incubated at 37 0 C for several or 24 hours.
  • 20 ⁇ l from each well are pipetted into new wells with 1 ml of broth and incubated at 37 0 C for 48 hours. If pre-formed biofilms are not completely killed by diluted polymer compositions, biofilms are formed in the wells.
  • the biofilms are stained with crystal violet.
  • the wells are visually inspected for biofilm development, and pictures are taken using a Kodak Image Analyzer. The results are indicated below.
  • Bact/Polymer refers to a mixture of bacteria and diluted polymer composition.
  • Surface refers to the well surface after dry gel is peeled off.
  • Fanm refers to the peeled off film. 0.3 ml P. aeruginosa is used instead of 0.2 ml because its biofilm tends to flow on the surface and attach to the air-liquid interface.
  • the MIC of the polymer composition to inhibit biofilm formation, and the capability of a series concentration of polymer composition to kill pre-formed biofilm upon drying, i.e., minimum tested concentration to completely kill biofilm (MTC), are shown in the table below.
  • the capability of the polymer composition from Example 3 to kill individual bacterial species or spores upon drying is determined.
  • the polymer composition from Example 3 is diluted with sterile nanopure water to prepare the following diluted polymer compositions: 50%, 25%, 10%, 0%.
  • 10 ⁇ l samples of bacteria ( ⁇ 10 6 ) overnight culture solutions are covered with 0.2 ml of each of the diluted polymer compositions and left at room temperature in a sterile hood for 12-24 hours. This results in the formation of polymer films.
  • Half of the films are peeled off and transferred to empty sterile wells, with the other half left in situ. 1 ml of broth is added to each well. After 1 - 2 hours incubation at 37°C, 20 ⁇ l of mixtures are pipetted from each well into a new well containing 1 ml broth. All the samples are incubated at
  • No represents no growth in all samples
  • No (N 1 /N2) represents Ni out of N 2 sample(s) has/have no growth.
  • Bact/Polymer refers to a mixture of bacteria and the diluted polymer composition.
  • Surface refers to the well surface after dry gel is peeled off.
  • Finm refers to the peeled off film in the well.
  • the polymer composition from Example 3 is diluted with sterile nanopure water to prepare the following diluted polymer compositions: 50%, 25%, 10%, 0%.
  • diluted polymer compositions 50%, 25%, 10%, 0%.
  • 10 ⁇ l of a solution containing S. subtilis spores ⁇ 10 5
  • 0.2 ml of the diluted polymer composition are covered with 0.2 ml of the diluted polymer composition and left at room temperature in a sterile hood for 25 hours.
  • Half of the resulting polymer films are peeled off and transferred to empty sterile wells, with the other half kept in situ. 1 ml broth is added to each well and incubated at 37°C for 24 hours.
  • MTC 10 concentration (MTC) to completely kill planktonic bacteria and spores for the species tested, upon drying, is as follows:
  • MBC minimum bactericidal concentration
  • MBC is the lowest concentration of a material that fully kills bacteria.
  • the polymer composition from Example 3 is diluted with sterile nanopure water to prepare a 25% or 50% polymer composition.
  • the following diluted polymer compositions are obtained by twofold series dilution with broth as diluent: 25%, 12.5%, 6.25%, 3.1%, 1.6%, 0.8%, 0.4%, 0.2%, 0.1%, and 0%.
  • Bacterial inoculum suspensions are obtained by inoculating 20 ⁇ l solutions of the bacteria ( ⁇ 2*10 6 ) overnight culture to 1 ml fresh broth medium.
  • Test samples are prepared by mixing 100 ⁇ l of bacterial inoculum suspensions with 100 ⁇ l of the diluted polymer compositions.
  • the MBC for S. aureus is determined.
  • the polymer composition from Example 1 is diluted with sterile nanopure water to prepare the following diluted polymer compositions: 10%, 5%, 1%, 0.5%, 0.1%, and 0%.
  • Test samples are prepared by mixing 1 ml of growth media with 0.2 ml of each of the diluted polymer compositions. These test samples are inoculated with 10 ⁇ l of bacteria ( ⁇ 10 6 ) for 24 hours. 10 ⁇ l of media are streaked on an LB plate and incubated at 37 0 C for 24 hours. Growth is visibly determined. The results are as follows:
  • Example 15 The residual kill potential of a peeled off film of the polymer composition from Example 3 is determined for certain species of bacteria.
  • the polymer composition from Example 3 is diluted with sterile nanopure water to prepare is used along with the following diluted polymer compositions: 100%, 50%, 25%, 10%, and 0%. (The 100% sample is not diluted.)
  • 0.2 ml samples of each of the polymer compositions are placed in wells. The polymer compositions are maintained in the wells at room temperature under a sterile hood for 24 hours. The polymer compositions dry to form film layers. The film layers are peeled off and discarded. 1 ml of broth inoculated with ⁇ . subtilis spores ( ⁇ 10 4 ) or E.
  • faecalis ( ⁇ 10 6 , or 10 5 ) are transferred to wells and incubated at 37°C for 48 hours. Three 200 ⁇ l samples from each well are transferred to a 96-well plate. Absorbance is measured at 595 nm using a 96- well plate reader. The results are as follows:
  • the killing efficacy of the polymer composition from Example 3 at the species-specific MBC as a function of exposure time is determined.
  • Example 3 10 7 S. aureus (MRSA), P. aeruginosa, and E. coli O157:H7 are incubated stationary in the absence or presence of the composition for Example 3 diluted to 12.5% for 24 hours at 37 0 C in an incubator. Starting from time 0, aliquots of 0.1 ml samples are removed for colony count plating every 2 hours for 12 hours, and at 24 hours. Colony numbers on agar plates are counted after 22-26 hours incubation at 37 0 C, and checked again after 36-48 hours. The bacteria killed (log reduction / percentage killed) after 12 hours and 24 hours by the composition from Example 3 diluted to 12.5% are as follows:
  • Yeast growth medium (YM) is inoculated with 1:20 dilution of an overnight growth of C. albicans, aliquoted in duplicates into 1 ml wells in the presence of the following diluted polymer compositions from Example 1 : 10%, 5%, 2.5%, 1.25% and 0%, and incubated for 24 hours at 37 0 C. Under these conditions, C. albicans grows predominantly as a biofilm on the bottom of the well.
  • [4,4-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) reagent is added for 2 hours, media is removed and the cells are solubilized in 100% dimethylsulfoxide (DMSO). 200 ⁇ l samples are aliquoted into a 96-well plate and read on a spectrophotometric plate reader. Absorbance is measured at 495 nm. The MIC of Example 1 in solution for C. albicans is determined to be 2.5%.
  • Example 1 The ability of Example 1 to kill individual fungal species in solution upon polymer drying is determined. 10 ⁇ l of overnight C. albicans growth is placed on the bottom of a 1 ml well and covered with 50 ⁇ l of undiluted polymer composition from Example 1 and allowed to dry overnight (in duplicates). The dried peel is removed and placed into a new well. 1 ml of yeast growth medium is added to the left-behind well and the peel-containing well. The wells are incubated for 24 hours to allow any residual viable yeast to proliferate. Neither set of wells has any growth as assessed by the MTT viability assay. The polymer composition from Example 1 , upon drying, kills all the C. albicans organisms trapped within the peel and leaves behind a sterile surface.
  • the residual kill potential of a peeled film formed from the polymer composition of Example 1 is determined for fungus.
  • the polymer composition from Example 1 as well as the following dilutions thereof using sterile nanopure water are used: 50%, 25%, 12%, 6%, and 0%.
  • 0.2 ml of each of the polymer compositions are placed in wells and maintained at room temperature in a sterile hood for 24 hours until dry. The resulting films are peeled off and discarded.
  • 2 ml of yeast growth media inoculated with 1 :20 overnight culture of C. albicans are added to each polymer-pre-treated well and allowed to incubate for 18 hours.
  • MTT reagent is added to each well and maintained therein for three hours. Cells are solubilized in 100% DMSO. Samples are placed on a spectrophotometric plate reader. Absorbance is measured at 495 nm.
  • the MTT-measured viability of C. albicans is as
  • the MIC against S. epidermidis is determined using a new polymer composition modified from Example 3.
  • the modified polymer composition is diluted with sterile nanopure water to prepare a 12.5% polymer composition.
  • the following diluted polymer compositions are obtained by twofold series dilution with broth as diluent: 6.25%, 3.1%, 1.6%, 0.8%, 0.4%, 0.2%, 0.1%, and 0%.
  • Bacteria inoculum suspension is obtained by inoculating 20 ⁇ l solutions of the bacteria ( ⁇ 2x10 6 ) overnight culture to 1 ml fresh broth medium.
  • Test samples are prepared by mixing 100 ⁇ l of bacterial inoculum suspensions with 100 ⁇ l of the diluted polymer compositions. The samples are incubated stationary at 37 0 C for 24 hours. The results are indicated below.
  • MIC minimum inhibitory concentrations
  • the minimum bactericidal concentration (MBC) of individual bacterial species is determined for polymer compositions described in Example 21.
  • the polymer compositions are diluted with sterile nanopure water to prepare 12.5% polymer compositions.
  • the following diluted polymer compositions are obtained by twofold series dilution with broth as diluent: 6.2%, 3.1%, 1.6%, 0.8%, 0.4%, 0.2%, 0.1%, and 0%.
  • Bacterial inoculum suspension is obtained by inoculating 20 ⁇ l solutions of the bacteria ( ⁇ 2 ⁇ 10 6 ) overnight culture to 1 ml fresh broth medium.
  • Test samples are prepared by mixing 100 ⁇ l of bacterial inoculum suspensions with 100 ⁇ l of the diluted polymer compositions.
  • Example 1 The toxicity of Example 1 is compared to Chlorohexidine gluconate (a commonly used oral antiseptic) to human HeLa cells in culture is determined.
  • HeLa cells are plated at subconfluency into a 96-well plate tissue culture plate, and after attachment, treated with the indicated final concentrations of Example 1 polymer or Chlorohexidine gluconate in triplicates. After 48 hours of culture, MTT reagent is added for two 2 hours to permit the development of viability-indicating color. 1 ⁇ M PAO (phenylarsine oxide) is used as a positive (effective killing) control.
  • Lethal dose 50 (LD 50 ) of Example 1 for HeLa cells is found to be ⁇ 0.025% and for chlorohexidine gluconate ⁇ 0.0004%.
  • Example 24 The inhibitory effect of the polymer against viral infectivity in is determined.
  • DMEM-FCS Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum
  • Three-fold dilutions thereof using DMEM-FCS are prepared: 20.0%, 13.32%, 8.87%, 5.91%, 3.93%, 2.62%, 1.75%, 1.16%, 0.77%, 0.52%, 0.34%, and 0% (containing no polymer composition) and added to a 96 well tissue culture plate in 8 parallel rows.
  • the polymer compositions are maintained in the wells at room temperature under a sterile hood for 24 hours.
  • the polymer compositions dry to form film layers.
  • the film layers are peeled off and rehydrated in 100 ⁇ l sterile nanopure water.
  • 100 ⁇ l of pox virus ( ⁇ 10 2 ) and 200 ⁇ l LB are placed in a well and mixed.
  • Three-fold dilutions thereof using DMEM-FCS are prepared: 10 2 , 6.66 2 , 4.44 2 , 2.95 2 , 1.97 2 , 1.31 2 , 8.72, and 0 (containing no virus) and added to a 96 well tissue culture plate in 12 parallel rows.
  • Test samples are prepared by mixing 50 ⁇ l of the diluted polymer compositions with 50 ⁇ l of viral concentrations into a well containing 100 ⁇ l (DMEM- FCS) and new tissue culture pre-seeded with HeLa cells ( ⁇ 10 4 /well).
  • the plate is incubated for 1-4 days, media replaced with 100 ⁇ l methycellulose-containing DMEM-FCS and the incubation continued for additional 2-
  • the pathologic effect of the virus is visually assessed for each column and row to determine the fold protective effect of the polymer as compared to the controls.
  • plaque forming units As viruses replicate in a cell, they spread to neighbor cells that have membrane contact. The infected cells will die resulting in plaque forming units (PFU) surrounded by living cells. The formation of plaques in living cells indicates the virus has survived and is killing the cells. Other viruses can take up to one week to show the development of PFU. One plaque forming unit indicates the polymer composition concentration did not prevent the virus from being pathogenic.
  • the potential for using a change in polymer color or fluorescence as an indicator of dryness is determined.
  • the polymer composition from Example 1 (containing McCormick blue food coloring) or polymer composition from Example 4 (containing Spectrazurine blue FGND-LIQ) is dried on a glass surface. Upon thorough drying, the gel with McCormick blue food coloring fluoresces bright red under UV light. This method of identifying if the polymer composition is fully dried is important when drying affects killing efficacy.
  • the inhibitory effect of a polymer that leaches out of a solid material (e.g. semi-solid) agarose is determined. 1 ml of 1 % agarose, containing the polymer composition from Example 1 diluted to a final concentration of 10%, 5%, 1 % or 0%, is allowed to harden. Segments of these materials are then placed on an LB plate that had been inoculated with ⁇ 10 5 S. epidermidis bacteria, the plate incubated at 37 0 C overnight so that the bacterial lawn forms where the conditions are conducive to cell viability and replication. A ring of clearance around the agarose indicates that the polymer has leached out of the agarose and protected the surrounding area from being populated by the bacteria. This is shown in Fig. 4 which indicates that the polymer composition at 5% and 10% leaches out of a semi-solid support (1 % agarose) and protects the surrounding area against proliferation of S. epidermis bacteria.
  • a solid material e.g. semi-solid
  • Example 1 polymer that leaches out of a solid material.
  • a series of ⁇ 3mm by 3mm cellulose filter paper fragments (Whatmann) are placed on a surface of an LB plate that had been inoculated with ⁇ 10 5 unknown bacteria ( likely many different species) that had grown out of partially cleaned Socorro sewage water.
  • 1ul of Example 1 5% (in water) polymer dilution, or water only is spotted on top of the filter.
  • the plate incubated at 37 0 C overnight so that the bacterial lawn forms where the conditions are conducive to cell viability and replication.
  • a ring of clearance around the filter paper indicates that the polymer has leached out of the filter paper and protected the surrounding area from being populated by the multiplicity of unknown environmental bacteria.
  • the inhibitory effect of the polymer composition from Example 1 that spreads over a moist surface that is conductive to germination of B. s ⁇ btilis spores is determined. 50 ⁇ l of the polymer from Example 1 is spotted on top of an LB that is inoculated with 10 5 B. subtilis spores. The plate is incubated (covered, kept moist) at 37 0 C overnight. Where the conditions are conducive to spore germination and bacterial replication, a lawn is formed. A large ring of clearance seen not just under but also around the area directly covered by the polymer indicates that the polymer has protected the surface underneath itself and that the protective action leached out of the polymer and additionally protected the surrounding area from being populated by B. subtilis bacteria.
  • FIG. 6 This is shown in Fig. 6.
  • This example shows that the polymer composition from Example 1 does not need to dry to inhibit spore germination and subsequent bacterial proliferation since the plate is kept moist throughout the incubation period.
  • Fig. 6 shows killing of bacterial spores and prevention of the germinated B. subtilis bacteria.
  • Area A is covered by the polymer.
  • Area B is not covered by the polymer.
  • Small ( ⁇ 5 ⁇ l) samples of areas A and B are placed either into 25 ml or 150 ml of nutrient media to dilute out the polymer and allow bacterial outgrowth upon incubation at 37 0 C for 48 hours. No growth is observed.
  • 10 ⁇ l of each of the media (after 48 hour incubation) are streaked onto an LB plate. If there are any viable spores or planktoninc bacteria left in the area of clearance, colonies would form. No colonies formed, indicating that areas A and B are sterile.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Abstract

L'invention concerne un procédé qui consiste à mettre en contact un micro-organisme et/ou un agent infectieux avec une dose efficace d'une composition polymère en vue de réduire ou d'éliminer la reproductivité, le métabolisme, la croissance et/ou la pathogénicité du micro-organisme et/ou de l'agent infectieux, la composition polymère comprenant de l'eau, un polymère filmogène soluble dans l'eau, un agent chélaté et un tensio-actif.
PCT/US2008/067441 2007-06-19 2008-06-19 Procédé de traitement de micro-organismes et/ou d'agents infectieux WO2008157664A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2690843A CA2690843A1 (fr) 2007-06-19 2008-06-19 Procede de traitement de micro-organismes et/ou d'agents infectieux
EP08771435A EP2173161A1 (fr) 2007-06-19 2008-06-19 Procédé de traitement de micro-organismes et/ou d'agents infectieux
JP2010513399A JP2010531168A (ja) 2007-06-19 2008-06-19 微生物及び／又は感染体を処理する方法
CN200880103309A CN101815435A (zh) 2007-06-19 2008-06-19 处理微生物和/或传染原的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94483807P 2007-06-19 2007-06-19
US60/944,838 2007-06-19

Publications (1)

Publication Number Publication Date
WO2008157664A1 true WO2008157664A1 (fr) 2008-12-24

Family

ID=39683695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/067441 WO2008157664A1 (fr) 2007-06-19 2008-06-19 Procédé de traitement de micro-organismes et/ou d'agents infectieux

Country Status (7)

Country Link
US (1) US20080317702A1 (fr)
EP (1) EP2173161A1 (fr)
JP (1) JP2010531168A (fr)
KR (1) KR20100031505A (fr)
CN (1) CN101815435A (fr)
CA (1) CA2690843A1 (fr)
WO (1) WO2008157664A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104893998A (zh) * 2014-10-10 2015-09-09 上海大学 一种普洱普鲁蓝菌及其培养方法
CN105132305A (zh) * 2015-07-09 2015-12-09 上海大学 假单胞菌属菌株及其筛选方法
AU2015261645B2 (en) * 2011-05-10 2017-10-19 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
WO2018042435A1 (fr) * 2016-08-31 2018-03-08 Nontoxico Ltd Composition antiparasitaire et procédé associé

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154953A2 (fr) 2011-05-10 2012-11-15 Microbial Defense Systems, Llc Matériau solide antimicrobien et ses procédés de fabrication et d'utilisation
RU2619227C2 (ru) 2011-12-15 2017-05-12 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Водный суспензионный концентрат с высоким содержанием активного ингредиента
CA2783349A1 (fr) * 2012-07-18 2014-01-18 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Environment Decontamination des radionucleides sur des materiaux de construction
WO2014201544A1 (fr) 2013-06-18 2014-12-24 Chemgreen Innovation Inc. Polymère antimicrobien comportant un groupe ammonium quaternaire
CN104233331B (zh) * 2014-09-11 2016-06-29 南京农业大学 食品不锈钢加工器械表面致病菌生物菌膜的清除方法
MX2020003946A (es) * 2017-10-18 2020-08-03 Solenis Tech Lp Composiciones que exhiben sinergia en el control de biopeliculas.
EP3697212B1 (fr) 2017-10-18 2023-01-18 Solenis Technologies, L.P. Compositions faisant preuve de synergie dans la lutte contre les biofilms
WO2019200025A1 (fr) * 2018-04-11 2019-10-17 New Mexico Tech University Research Park Corporation Formulations anti-infectieuses
WO2022013642A1 (fr) * 2020-07-16 2022-01-20 3M Innovative Properties Company Copolymères contenant du phosphate permettant la suppression de la virulence

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482680A (en) * 1981-09-15 1984-11-13 Dynapol Quaternary ammonium group-containing polymers having antimicrobial activity
EP0916682A1 (fr) * 1997-11-14 1999-05-19 Menicon Co., Ltd. Polymère antibactérien soluble dans l'eau et composition liquide pour lentilles de contact le contenant
US20020122831A1 (en) * 2000-11-29 2002-09-05 Mowrey-Mckee Mary Aqueous disinfecting systems
US20040013638A1 (en) * 1999-08-09 2004-01-22 Eric Aubay Use of a water-soluble polymer in a biocidal composition for the treatment of hard surfaces
US20050079150A1 (en) * 2003-09-04 2005-04-14 Gellman Samuel H. Biocidal polymers
WO2005085406A1 (fr) * 2004-02-27 2005-09-15 Reckitt Benckiser (Uk) Limited Procede de traitement d'une surface
US20050277568A1 (en) * 2004-06-14 2005-12-15 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Fibrous elastic gel cleansing article
WO2006081617A1 (fr) * 2005-02-02 2006-08-10 Novapharm Research (Australia) Pty Ltd Polymere biostatique
WO2007100861A1 (fr) * 2006-02-28 2007-09-07 Cellular Bioengineering, Inc. Composition de polymère et procédé servant à enlever des contaminants d'un substrat

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097437A (en) * 1977-05-27 1978-06-27 M & T Chemicals Inc. Thixotropic aqueous coating composition of solubilized polymer with dispersion of quaternary ammonium clay in aliphatic hydrocarbon
US4241141A (en) * 1979-03-19 1980-12-23 S. C. Johnson & Son, Inc. Removable coatings which prevent penetration from felt tip marking inks
US4598122A (en) * 1985-01-22 1986-07-01 Ciba-Geigy Corporation Polyoxirane crosslinked polyvinyl alcohol hydrogel contact lens
US4748049A (en) * 1986-03-27 1988-05-31 Chemfil Corporation Clear paint booth coating composition and method
US4978713A (en) * 1987-12-16 1990-12-18 Ciba-Geigy Corporation Polyvinyl alcohol derivatives containing pendant vinylic monomer reaction product units bound through ether groups and hydrogel contact lenses made therefrom
US5133117A (en) * 1988-12-13 1992-07-28 Isotron Device for applying spreadable coatings
US5143949A (en) * 1989-01-23 1992-09-01 Groco Specialty Coatings Company Aqueous based, strippable coating composition and method
US5091447A (en) * 1989-05-08 1992-02-25 Isotron In-situ polymeric membrane for cavity sealing and mitigating transport of liquid hazardous materials based on aqueous epoxy-rubber alloys
US5405509A (en) * 1989-05-08 1995-04-11 Ionex Remediation of a bulk source by electropotential ion transport using a host receptor matrix
US5174929A (en) * 1990-08-31 1992-12-29 Ciba-Geigy Corporation Preparation of stable polyvinyl alcohol hydrogel contact lens
AU664050B2 (en) * 1991-12-18 1995-11-02 Becton Dickinson & Company Process for lysing mycobacteria
DE4201800A1 (de) * 1992-01-23 1993-07-29 Wacker Chemie Gmbh Beschichtung von substratoberflaechen
US5421897A (en) * 1992-07-17 1995-06-06 Grawe; John Abatement process for contaminants
EP0587383A1 (fr) * 1992-09-10 1994-03-16 Halliburton Company Méthode de fabrications d'une agglomération de ciment.
TW272976B (fr) * 1993-08-06 1996-03-21 Ciba Geigy Ag
US5387434A (en) * 1993-09-01 1995-02-07 Bat Technologies Inc. Anti-graffiti coating material and method of using same
JP3046918B2 (ja) * 1994-10-17 2000-05-29 クレオール株式会社 塗装面の洗浄方法
US5631042A (en) * 1995-10-06 1997-05-20 Foster S. Becker Graffiti-resistant barriers, related compositions and methods24m
JP2868206B2 (ja) * 1996-04-16 1999-03-10 株式会社オフテクス 消毒および／または防腐のための有害微生物防除用組成物
US5731057A (en) * 1996-05-08 1998-03-24 Montoya; Louis Protective barrier composition and surface protection method
US6139963A (en) * 1996-11-28 2000-10-31 Kuraray Co., Ltd. Polyvinyl alcohol hydrogel and process for producing the same
JP3107030B2 (ja) * 1997-03-14 2000-11-06 鹿島建設株式会社 構造物表面の洗浄方法
CA2287163A1 (fr) * 1997-04-24 1998-10-29 Church & Dwight Co., Inc. Compositions destinees a tuer des acariens detriticoles et techniques d'utilisation
US5753563A (en) * 1997-07-30 1998-05-19 Chartered Semiconductor Manufacturing Ltd. Method of removing particles by adhesive
US6849328B1 (en) * 1999-07-02 2005-02-01 Ppg Industries Ohio, Inc. Light-transmitting and/or coated article with removable protective coating and methods of making the same
US6710126B1 (en) * 1999-11-15 2004-03-23 Bio Cure, Inc. Degradable poly(vinyl alcohol) hydrogels
DE10013995A1 (de) * 2000-03-22 2001-09-27 Chemagen Biopolymer Technologi Magnetische, silanisierte Trägermaterialien auf Basis von Polyvinylalkohol
US20020086936A1 (en) * 2000-12-28 2002-07-04 Eoga Anthony B. Anti soiling coating composition and process for use thereof
US6855743B1 (en) * 2001-10-29 2005-02-15 Nanosystems Research, Inc. Reinforced, laminated, impregnated, and composite-like materials as crosslinked polyvinyl alcohol hydrogel structures
AU2003234159A1 (en) * 2002-04-22 2003-11-03 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
US20060018853A1 (en) * 2002-11-18 2006-01-26 Kose Corporation Cosmetic pack preparation
US7314857B2 (en) * 2003-08-25 2008-01-01 Kane Biotech Inc. Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
WO2005031757A1 (fr) * 2003-09-23 2005-04-07 Microtek Medical Holdings, Inc. Revetements en pval pelables et procedes de fabrication correspondants
JP2007091666A (ja) * 2005-09-29 2007-04-12 Daikin Ind Ltd スライム抑制方法、ドレンアップ装置、空気調和機、水路及びスライム剥離剤
AU2007221203B2 (en) * 2006-02-23 2013-02-21 The Chemours Company Fc, Llc Removable antimicrobial coating compositions and methods of use
EP2162498B1 (fr) * 2007-06-19 2011-04-13 Cellular Bioengineering, Inc. Méthode permettant de protéger des substrats et de retirer des agents contaminants de ces substrats

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482680A (en) * 1981-09-15 1984-11-13 Dynapol Quaternary ammonium group-containing polymers having antimicrobial activity
EP0916682A1 (fr) * 1997-11-14 1999-05-19 Menicon Co., Ltd. Polymère antibactérien soluble dans l'eau et composition liquide pour lentilles de contact le contenant
US20040013638A1 (en) * 1999-08-09 2004-01-22 Eric Aubay Use of a water-soluble polymer in a biocidal composition for the treatment of hard surfaces
US20020122831A1 (en) * 2000-11-29 2002-09-05 Mowrey-Mckee Mary Aqueous disinfecting systems
US20050079150A1 (en) * 2003-09-04 2005-04-14 Gellman Samuel H. Biocidal polymers
WO2005085406A1 (fr) * 2004-02-27 2005-09-15 Reckitt Benckiser (Uk) Limited Procede de traitement d'une surface
US20050277568A1 (en) * 2004-06-14 2005-12-15 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Fibrous elastic gel cleansing article
WO2006081617A1 (fr) * 2005-02-02 2006-08-10 Novapharm Research (Australia) Pty Ltd Polymere biostatique
WO2007100861A1 (fr) * 2006-02-28 2007-09-07 Cellular Bioengineering, Inc. Composition de polymère et procédé servant à enlever des contaminants d'un substrat

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015261645B2 (en) * 2011-05-10 2017-10-19 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
AU2017232218B2 (en) * 2011-05-10 2019-07-04 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
CN104893998A (zh) * 2014-10-10 2015-09-09 上海大学 一种普洱普鲁蓝菌及其培养方法
CN105132305A (zh) * 2015-07-09 2015-12-09 上海大学 假单胞菌属菌株及其筛选方法
WO2018042435A1 (fr) * 2016-08-31 2018-03-08 Nontoxico Ltd Composition antiparasitaire et procédé associé

Also Published As

Publication number Publication date
KR20100031505A (ko) 2010-03-22
CN101815435A (zh) 2010-08-25
EP2173161A1 (fr) 2010-04-14
US20080317702A1 (en) 2008-12-25
CA2690843A1 (fr) 2008-12-24
JP2010531168A (ja) 2010-09-24

Similar Documents

Publication Publication Date Title
US20080317702A1 (en) Method for treating microorganisms and/or infectious agents
US8110538B2 (en) Peracid/peroxide composition and use thereof as an anti-microbial and a photosensitizer
Oule et al. Akwaton, polyhexamethylene-guanidine hydrochloride-based sporicidal disinfectant: a novel tool to fight bacterial spores and nosocomial infections
Ibrahim et al. Antimicrobial agents for textiles: types, mechanisms and analysis standards
JP7066628B2 (ja) 抗微生物性布帛アセンブリ
JP2009519220A (ja) 病原体‐制御薬剤
US20070134302A1 (en) Antimicrobial substrates with peroxide treatment
Immerseel et al. Cleaning and disinfection.
KR910001409B1 (ko) 살균 조성물 및 그의 제조방법
US11279902B2 (en) Hyperprotonation cleaning, disinfection, and sterilization compositions and methods
KR20200084035A (ko) 생물막의 제거 방법
JPH02504401A (ja) 殺微生物性洗浄処方物または消毒処方物およびその製造方法
Rajitha et al. Assessment of alkylimidazolium chloride ionic liquid formulations for cleaning and disinfection of environmental surfaces
Gouveia et al. Antifungal activity of components used for decontamination of dental prostheses on the growth of Candida albicans
Wirtanen et al. Sanitation in dairies
Moraes et al. Evaluation of new antimicrobial products based on potassium monopersulfate for disinfection of poultry farms
RU2718910C1 (ru) Индикатор для выявления биологических плёнок бактерий на медицинских инструментах (варианты)
Venne et al. Innovations in Textile Technology Against Pathogenic Threats: A Review of the Recent Literature
Moraes et al. Atividade antimicrobiana de produtos à base de monopersulfato de potássio em bactérias associadas a infecções aviárias
Melo et al. A Multi-Purpose Approach to the Mechanisms of Action of Two Biocides (Benzalkonium Chloride and Dibromonitrilopropionamide): Discussion of Pseudomonas fluorescens' Viability and Death
Saseendran Nair Biocide options to control the transmission of pathogens
Moraes et al. Antimicrobial activity of products based on potassium monopersulfate on bacteria associated with avian infections
GB2410958A (en) Cleaning composition
AU2014292797A1 (en) Improved bio-repellent hygiene system
WO2023150650A2 (fr) Compositions pour exposer des microbes filmogènes et procédés d'utilisation des compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880103309.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08771435

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2690843

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20097026474

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010513399

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008771435

Country of ref document: EP